Alda L. Tam, MD, FRCPC, MBA

SIO Session at CIO: Oligometastatic Disease — Definitions and Rationale

Alda Tam, MD, Professor, The University of Texas M.D. Anderson Cancer Center, University of Texas MD Anderson Cancer Center presents definitions and rationale behind the treatment of olig...

Alda L. Tam , MD, FRCPC, MBA;

07/27/2021

Lung Ablation: Patient and Lesion Selection

Alda Tam, MD, Professor, University of Texas MD Anderson Cancer Center, presents at CIOctober 2020.

Alda L. Tam , MD, FRCPC, MBA;

07/28/2021

Ablation 101

Alda L. Tam , MD, FRCPC, MBA;

01/28/2022

Best First Cases to Develop Your Practice

Alda L. Tam , MD, FRCPC, MBA;

02/08/2022

Where Does IO Stand in the NCCN Guidelines: Lung and Metastases to the Lung

Alda L. Tam , MD, FRCPC, MBA;

02/16/2022

Where Does IO Stand in the NCCN Guidelines: Panel Discussion

Nima Kokabi , MD;

Ahmed K. Abdel Aal , MD, PhD;

Nicholas Fidelman , MD;

Alda L. Tam , MD, FRCPC, MBA;

Nadine Abi-Jaoudeh , MD;

Daniel B. Brown , MD, FSIR;

02/16/2022

Lung and Kidney Disease Audience Q&A

Ron Arrellano , MD;

Robert Suh , MD;

Alda L. Tam , MD, FRCPC, MBA;

Timothy McClure , MD;

Constantino S. Peña , MD, FAHA, FSCCT, FSIR;

02/08/2022

Present State of MSK Interventions

Alda L. Tam , MD, FRCPC, MBA;

11/13/2019

Case Presentations: Cases I Should Be Doing

Alda L. Tam , MD, FRCPC, MBA;

Matthew Callstrom , MD, PhD;

11/12/2019

CIO Spotlight: Dr Tam on the Role of Biopsy in 2017

02/19/2017

Alda L. Tam , MD, FRCPC, MBA;

Alda Tam, MD Dr Alda Tam presented the session Understanding the Role of Biopsy at the 2017 Clinical Interventional Oncology Symposium. In this article, Dr Tam provides the reader with a full deciphering of her presentation. Here she...

Alda Tam, MD Dr Alda Tam...

02/19/2017

IO Learning